Abstract
Rationale
Function in society can be severely affected by disruptive behaviors in adults.
Objectives
To examine the efficacy and safety of risperidone in the treatment of disruptive behavior disorders in intellectually disabled adults.
Methods
Intellectually disabled patients with disruptive behavior disorder were randomly assigned to receive risperidone (n=39) in a flexible dosage ranging from 1 to 4 mg/day (mean dosage, 1.45±0.08 mg/day) or placebo (n=38) for 4 weeks of double-blind treatment. Efficacy at endpoint was measured primarily by using the Aberrant Behavior Checklist (ABC); secondary efficacy measures included the Behavior Problems Inventory and Clinical Global Impressions scales. After this 4-week period, patients could enter open-label treatment with risperidone for 48 weeks.
Results
Risperidone was well tolerated, and patients treated with risperidone demonstrated significantly greater improvement at endpoint on the ABC than those who received placebo [−27.3 points (52.8% improvement) versus −14.9 points (31.3% improvement); P=0.036] and also improved on Behavior Problems Inventory and Clinical Global Impressions ratings. Over the 48-week, open-label follow-up period, there was a further decrease of 6.3 points (P≤0.05) on the ABC for patients who initially received risperidone and a decrease of 11.3 points (P≤0.05) for patients who initially received placebo and were switched to open-label risperidone. These results were achieved with a mean modal dosage of 1.8 mg/day.
Conclusion
Risperidone is efficacious and well tolerated in managing disruptive behavior disorders in adults with intellectual disability.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(Suppl 7):22–31
Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485–491
Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, and the Risperidone Disruptive Behavior Study Group (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337–1346
Brar JS, Ganguli, R, Pandina, G, Turkoz I, Berry S, Mahmoud R (in press) Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry
Buitelaar JK (2000) Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnosis and aggressive behavior. J Child Adolesc Psychopharmacol 10:19–26
Chouinard G, Ross-Canard A, Annable L, Jones BD (1980) The extrapyramidal symptom rating scale [abstract]. Can J Neurol Sci 7:233
Cohen SA, Ihrig K, Lott RS, Kerrick JM (1998) Risperidone for aggression and self-injurious behavior in adults with mental retardation. J Autism Dev Disord 28:229–233
Csernansky JG, Mahmoud R, Brenner R (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16–22
Dartnall NA, Holmes JP, Morgan SN, McDougle CJ (1999) Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord 29:87–91
Emerson E, Kiernan C, Alborz A, Reeves D, Mason H, Swarbrick R, Mason L, Hatton C (2001) The prevalence of challenging behaviors: a total population study. Res Dev Disabil 22:77–93
Farrington DP, Gallagher B, Morley L, St Ledger RJ, West DJ (1988) Are there any successful men from criminogenic backgrounds? Psychiatry 51:116–130
Fergussen DM, Horwood LJ (1998) Early conduct problems and later life opportunities. J Child Psychol Psychiatry 39:1097–1108
Findling RL, Maxwell K, Wiznitzer M (1997) An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 33:155–159
Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL (2000) A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psych 39:509–516
Guy W (1976) Clinical global impressions. In: ECDEU assessment manual for psychopharmacology, revised 1976. National Institute of Mental Health, Rockville, MD, pp 217–222
McDougle CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price LH (1995) Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol 5:273–282
McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ (1997) Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Am Acad Child Adolesc Psych 36:683–693
Nicolson R, Awad G, Sloman L (1998) An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psych 37:372–376
Purdon SE, Lit W, Labelle A, Jones BD (1994) Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 39:400–405
Robins LN (1966) Deviant children grow up: a sociological and psychiatric study of sociopathic personality. Williams & Wilkins, Baltimore, MD
Rojahn J (1992) Behavior problems inventory: a prospectus. Nisonger Center for Mental Retardation and Developmental Disabilities, Ohio State University
Santosh PJ, Baird G (1999) Psychopharmacotherapy in children and adults with intellectual disability. Lancet 354:233–242
Simon EW, Blubaugh KM, Pippidis M (1996) Substituting traditional antipsychotics with risperidone for individuals with mental retardation. Ment Retard 34:359–366
Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, and the Risperidone Conduct Study Group (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psych 41:1026–1036
Swann AC (2003) Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry 64(Suppl 4):26–35
Turgay A, Binder C, Snyder R, Fisman S (2002) Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34
Van Bellinghen M, De Troch C (2001) Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11:5–13
Van Elteren PH (1960) On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 37:351–361
Vanden Borre R, Vermote R, Buttiens M, Thiry P, Dierick G, Geutjens J, Sieben G, Heylen S (1993). Risperidone as add-on therapy in behavioral disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 87:167–171
Werneke U, Taylor D, Sanders TAB (2002) Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 17:145–160
Zarcone JR, Hellings JA, Crandall K, Reese RM, Marquis J, Fleming K, Shores R, Williams D, Schroeder SR (2001) Effects of risperidone on aberrant behavior of persons with developmental disabilities: a double-blind crossover study using multiple measures. Am J Ment Retard 106:525–538
Acknowledgements
This work was supported by Johnson & Johnson Pharmaceutical Research & Development.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gagiano, C., Read, S., Thorpe, L. et al. Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. Psychopharmacology 179, 629–636 (2005). https://doi.org/10.1007/s00213-004-2093-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-004-2093-2